Classification Nuance. The OpenFDA dataset, which draws from the Structured Product Labeling (SPL) files, often includes multiple classification fields, and the specific string "Phosphate Binder [EPC]" may only be assigned to a single product. The other drugs are likely classified using: More Specific Classes: Many of those drugs (like sevelamer, ferric citrate, etc.) may be classified by their specific mechanism or chemical group, which also acts as a phosphate binder. Example: A drug might be classified as "Iron-Containing Compound [EPC]" or "Aluminum-Containing Compound [EPC]" instead of the more general "Phosphate Binder [EPC]". Different Classification Fields: The NDC data contains several classification fields. You might be checking the Established Pharmacological Class (pharm_class_epc), but the other drugs might be listed under: Mechanism of Action (pharm_class_moa), Physiological Effect (pharm_class_pe)
  Home  

Enter a class name or drug name above to search the database.

Vascular Endothelial Growth Factor Inhibitor [EPC]

NDC Number Brand Name Generic Name Manufacturer Dosage Form DEA Sch. Marketing Start Date
0024-5840 ZALTRAP ziv-aflibercept sanofi-aventis U.S. LLC SOLUTION, CONCENTRATE 2012-08-03
0024-5841 ZALTRAP ziv-aflibercept sanofi-aventis U.S. LLC SOLUTION, CONCENTRATE 2012-08-03
0069-0315 Zirabev bevacizumab-bvzr Pfizer Laboratories Div Pfizer Inc INJECTION, SOLUTION 2020-01-13
0069-0342 Zirabev bevacizumab-bvzr Pfizer Laboratories Div Pfizer Inc INJECTION, SOLUTION 2020-01-13
50242-060 Avastin bevacizumab Genentech, Inc. INJECTION, SOLUTION 2004-02-26
50242-061 Avastin bevacizumab Genentech, Inc. INJECTION, SOLUTION 2004-02-26
50242-078 Susvimo Ranibizumab Genentech, Inc. INJECTION, SOLUTION 2021-10-22
50242-080 LUCENTIS RANIBIZUMAB Genentech, Inc. INJECTION, SOLUTION 2006-06-30
50242-082 LUCENTIS RANIBIZUMAB Genentech, Inc. INJECTION, SOLUTION 2012-08-10
55513-056 PAVBLU aflibercept-ayyh Amgen, Inc INJECTION, SOLUTION 2024-10-28
55513-065 PAVBLU aflibercept-ayyh Amgen, Inc INJECTION, SOLUTION 2024-10-28
55513-206 MVASI bevacizumab-awwb Amgen Inc INJECTION, SOLUTION 2018-06-01
55513-207 MVASI bevacizumab-awwb Amgen Inc INJECTION, SOLUTION 2018-06-01
61314-624 CIMERLI ranibizumab-eqrn Sandoz Inc INJECTION, SOLUTION 2024-12-12
61314-625 CIMERLI ranibizumab-eqrn Sandoz Inc INJECTION, SOLUTION 2024-12-12
61755-005 EYLEA aflibercept Regeneron Pharmaceuticals, Inc. INJECTION, SOLUTION 2011-11-21
61755-050 EYLEA HD aflibercept Regeneron Pharmaceuticals, Inc INJECTION, SOLUTION 2023-08-18
61755-051 EYLEA HD aflibercept Regeneron Pharmaceuticals, Inc INJECTION, SOLUTION 2023-08-18
64406-019 Byooviz ranibizumab-nuna BIOGEN INC. INJECTION, SOLUTION 2022-06-01
70114-440 CIMERLI ranibizumab-eqrn Coherus BioSciences Inc INJECTION, SOLUTION 2022-10-03
70114-441 CIMERLI ranibizumab-eqrn Coherus BioSciences Inc INJECTION, SOLUTION 2022-10-03
70121-1754 ALYMSYS bevacizumab-maly Amneal Pharmaceuticals LLC INJECTION, SOLUTION 2022-04-15
70121-1755 ALYMSYS bevacizumab-maly Amneal Pharmaceuticals LLC INJECTION, SOLUTION 2022-04-15
72606-011 Vegzelma bevacizumab-adcd CELLTRION USA, Inc. INJECTION, SOLUTION 2023-04-03
72606-012 Vegzelma bevacizumab-adcd CELLTRION USA, Inc. INJECTION, SOLUTION 2023-04-03
83257-009 JOBEVNE bevacizumab-nwgd Biocon Biologics Inc. INJECTION 2025-04-10
83257-010 JOBEVNE bevacizumab-nwgd Biocon Biologics Inc. INJECTION 2025-04-10



 [EPC] Established Pharmacological Classification 

Loading full table content...